Solid Tumors Clinical Trial
Official title:
A PHASE I, OPEN LABEL, DOSE-ESCALATION TRIAL EVALUATING THE SAFETY AND TOLERABILITY OF EF-022 (MODIFIED VITAMIN D BINDING PROTEIN MACROPHAGE ACTIVATOR) IN SUBJECTS WITH ADVANCED SOLID MALIGNANCIES
Activated macrophages, present in excess during natural inflammatory responses, bear the
potential to kill and eradicate cancer cells. Macrophage activation has been demonstrated to
require the serum-borne vitamin D binding protein (known as Gc protein), as well as B and T
lymphocytes. However, in various cancer patients the Gc protein is deglycosylated by serum
α-N-acetyl galactosaminidase (Nagalase) secreted from cancer cells. This deglycosylated Gc
protein, lacking the N-acetylgalactosamine monosaccharide, cannot be converted to its form
of Macrophage Activating Factor, leading to immunosuppression rather than Macrophage
activation against cancer cells.
Efranat has developed cancer immunotherapy based on Macrophage Activating Factor produced
from natural Gc protein extracted from FDA approved healthy human plasma.
In this phase I study, the treatment is given as Intramuscular, once-weekly injection of
EF-022, for two courses, while each course is comprised of 4 injections.
The investigational treatment is expected to enhance immune response, thereby, improve
patient's well being, quality of life and disease control.
Primary objectives:
1. To determine the safety and tolerability of EF-022 and to define the maximal tolerated
dose (MTD) for potential administration.
2. To identify the Dose Limiting Toxicity (DLT) of EF-022.
Secondary objectives:
1. To determine the 'Recommended Phase 2 Dose' (RP2D) based on MTD data, immunological and
pharmacodynamics markers
2. To explore preliminary efficacy of EF-022 in advanced solid tumors according to the
'Response Evaluation Criteria in the modified Solid Tumors' (RECIST 1.1) and blood
levels of tumor-related markers known to reflect tumor burden.
Exploratory objectives:
1. To assess levels of immune-related factors in peripheral blood (determined by FACS
analysis), reflecting induced immunological activities, including but not limited to,
natural killer (NK), monocytes (M1 and M2) and T cell subpopulations (effector vs
regulatory, CD4+ and CD8+ cells), B cells (CD20), myeloid and dendritic cells etc.
2. To assess the change in serum levels of protein biomarkers in the blood.
3. To immunohistochemically assess and compare tumor derived tissue samples Pre and post
treatment. To analyze the infiltration of different population of cells into the tumor
bed.
Part 1:
Eligible subjects will be assigned, successively in order of accrual, to one of the three
cohorts, to receive intramuscular (IM) injections of EF-022, once weekly for two courses of
treatment. Each course will consist of 4 injections with one week intervals (total: 8 weeks
of treatment).
Dose escalation will only proceed in the absence of dose-limiting toxicity (DLT) during
course 1. For this purpose, each cohort will only begin its first course of EF-022 when the
cohort preceding it has successfully completed its first 4-week treatment course without any
signs of DLT. During this first course, should 1/3 patients experience DLT, dose escalation
for the next cohort will not be authorized; the next cohort will receive the same dose as
the one preceding it. If 2 patients or more of all patients treated with a given dose
develop DLT, dose escalation will be halted and no more patients will be treated at the DLT
dose. The value of MTD will be defined as the EF-022 dose below the dose at which DLT was
seen for at least 2 subjects. Upon determination of the MTD, an additional cohort will be
opened (confirmatory cohort) and treated with two courses of that dose.
Part 2:
During the expanded cohort, 24 Patients will be allocated to receive either 100ng, 500ng or
1000ng weekly treatment as detailed below: The first 18 patients will be assigned to
alternating doses of either 100ng or 500ng in a sequential manner (each patient will be
assigned to a single dose), with the caveat that given indications should be assigned
equally, as much as possible, between these two doses.
Interim analysis will be performed once the 12th patient reaches Day 57 and the CT results
as well as PD analysis are available for at least 12 patients, while at least 18 patients
have begun study treatment. A decision regarding adding a 1000ng dose cohort vs. continuing
with the 100ng and 500ng doses will be based on a discussion of the interim analysis
results.
Each patient will receive 2 courses of treatment, i.e. weekly injections for a total period
of 8 weeks, followed by a follow-up period of up to 12 months from the start of treatment
(Day 1).
Continuation of treatment after the second course will be at the discretion of the
investigator. Patients who will continue extended treatment post course 2 will keep the
weekly injection dosage mode and continue therapy until disease progression, development of
unacceptable toxicities, non-compliance, inter-current illness that prevents treatment
continuation, withdrawal of consent, or change in subject condition that renders the subject
unacceptable for further treatment.
All study patients who completed at least two courses of treatment will be followed up until
12 months from day 1 of treatment.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT00750841 -
Study of the Effect of Rifampicin on the Pharmacokinetics (PK) of Multiple Doses of Cediranib in Patients With Solid Tumours
|
Phase 1 | |
Withdrawn |
NCT05419817 -
Pembrolizumab With Sitravatinib in Recurrent Endometrial Cancer and Other Solid Tumors With Deficient Mismatch Repair System
|
Phase 2 | |
Completed |
NCT02828930 -
A Study to Determine the Excretion Balance, Pharmacokinetics, Metabolism and Absolute Oral Bioavailability of a Single Oral Dose of [14C]-Labeled Idasanutlin and an Intravenous Tracer Dose of [13C]-Labeled Idasanutlin in a Single Cohort of Participants With Solid Tumors (Malignancies)
|
Phase 1 | |
Completed |
NCT01197170 -
Hormone Receptor Positive Disease Across Solid Tumor Types: A Phase I Study of Single-Agent Hormone Blockade and Combination Approaches With Targeted Agents to Provide Synergy and Overcome Resistance
|
Phase 1 | |
Completed |
NCT03258515 -
A Study to Investigate the Effect of Single Dose of AZD6094 (600 mg) on Cardiac Repolarization in Healthy Volunteers
|
Phase 1 | |
Terminated |
NCT03225105 -
M3541 in Combination With Radiotherapy in Solid Tumors
|
Phase 1 | |
Completed |
NCT01497925 -
Ph 1 Trial of ADI-PEG 20 Plus Docetaxel in Solid Tumors With Emphasis on Prostate Cancer and Non-Small Cell Lung Cancer
|
Phase 1 | |
Completed |
NCT01878890 -
Phase I Dose Escalation Trial of Efavirenz in Solid Tumours or Non-Hodgkin Lymphoma in Therapeutic Failure.
|
Phase 1 | |
Active, not recruiting |
NCT05059522 -
Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing
|
Phase 3 | |
Active, not recruiting |
NCT03634982 -
Dose Escalation of RMC-4630 Monotherapy in Relapsed/Refractory Solid Tumors
|
Phase 1 | |
Recruiting |
NCT04685226 -
A Phase I/II Clinical Trial of ICP-723 in the Treatment of Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT03175224 -
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
|
Phase 2 | |
Recruiting |
NCT06036121 -
A Study of ADRX-0706 in Select Advanced Solid Tumors
|
Phase 1 | |
Active, not recruiting |
NCT03258151 -
Association of Genetic Polymorphisms With Docetaxel-based Chemotherapy Toxicities in Chinese Solid Tumor Patients
|
||
Completed |
NCT01528046 -
Metformin in Children With Relapsed or Refractory Solid Tumors
|
Phase 1 | |
Recruiting |
NCT05325866 -
A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression
|
Phase 1/Phase 2 | |
Recruiting |
NCT04557449 -
Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors
|
Phase 1/Phase 2 | |
Terminated |
NCT02890368 -
Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides
|
Phase 1 | |
Completed |
NCT02759640 -
A Phase I Trial of HS-10241 in Solid Tumors
|
Phase 1 | |
Completed |
NCT02279433 -
A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-6051b
|
Phase 1 |